Claro Advisors LLC Lowers Holdings in Bristol Myers Squibb Company $BMY

Claro Advisors LLC trimmed its position in Bristol Myers Squibb Company (NYSE:BMY) by 28.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,159 shares of the biopharmaceutical company’s stock after selling 6,374 shares during the quarter. Claro Advisors LLC’s holdings in Bristol Myers Squibb were worth $748,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Trifecta Capital Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth $25,000. Accent Capital Management LLC purchased a new stake in shares of Bristol Myers Squibb in the 1st quarter worth $33,000. CBIZ Investment Advisory Services LLC lifted its holdings in shares of Bristol Myers Squibb by 66.0% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 231 shares during the period. GKV Capital Management Co. Inc. purchased a new stake in shares of Bristol Myers Squibb in the 1st quarter worth $36,000. Finally, REAP Financial Group LLC raised its position in shares of Bristol Myers Squibb by 202.8% in the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 428 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.07% of the company’s stock.

Analysts Set New Price Targets

BMY has been the subject of several recent research reports. Daiwa Capital Markets lowered Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a research report on Tuesday, August 5th. Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Dbs Bank raised Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Finally, Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fifteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $57.23.

Bristol Myers Squibb Trading Up 2.0%

Shares of NYSE:BMY opened at $46.50 on Thursday. The business’s 50-day moving average is $45.26 and its 200 day moving average is $46.73. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The firm has a market capitalization of $94.66 billion, a P/E ratio of 18.75, a P/E/G ratio of 2.23 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same period in the prior year, the company posted $1.80 EPS. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.3%. Bristol Myers Squibb’s dividend payout ratio is presently 83.78%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.